Infarmed Extends SNS Funding of Cystic Fibrosis Drugs to Patients Without the Common Mutation
Infarmed has approved SNS hospital funding for Kaftrio in patients aged 2 and over without the F508del mutation, and for Vertex's newer once-daily Alyftrek from age 6. Who qualifies, how they get it and what is still unknown.